Top

Journal of Neuro-Oncology

Published in:

01-12-2018 | Laboratory Investigation

Characterization of genomic alterations in primary central nervous system lymphomas

Authors: Soheil Zorofchian, Hanadi El-Achi, Yuanqing Yan, Yoshua Esquenazi, Leomar Y. Ballester

Published in: Journal of Neuro-Oncology | Issue 3/2018

Abstract

Purpose

Primary central nervous system lymphoma (PCNSL) is a non-Hodgkin lymphoma that affects the central nervous system (CNS). Although previous studies have reported the most common mutated genes in PCNSL, including MYD88 and CD79b, our understanding of genetic characterizations in primary CNS lymphomas is limited. The aim of this study was to perform a retrospective analysis investigating the most frequent mutation types, and their frequency, in PCNSL.

Methods

Fifteen patients with a diagnosis of PCNSL from our institution were analyzed for mutations in 406 genes and rearrangements in 31 genes by next generation sequencing (NGS).

Results

Missense mutations were identified as the most common mutation type (32%) followed by frame shift mutations (23%). The highest mutation rate was reported in the MYD88 (33.3%), CDKN2A/B (33.3%), and TP53 (26.7%) genes. Intermediate tumor mutation burden (TMB) and high TMB was detected in 13.3% and 26.7% of PCNSL, respectively. The most frequent gene rearrangement involved the IGH-BCL6 genes (20%).

Conclusions

This study shows the most common genetic alterations in PCNSL as determined by a commercial next generation sequencing assay. MYD88 and CD79b are frequently mutated in PCNSL, IGH-BCL6 is the most frequent gene rearrangement and approximately 1/4 of cases show a high TMB. Mutations in multiple genes, in addition to high TMB and gene rearrangements, highlights the complex molecular heterogeneity of PCNSL. Knowledge about genetic alterations in PCNSL can inform the development of novel targets for diagnosis and treatment.

Available only for authorised users

Li S, Young KH, Medeiros LJ (2018) Diffuse large B-cell lymphoma. Pathology 50:74–87. https://doi.org/10.1016/j.pathol.2017.09.006 CrossRefPubMed

Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937–1947. https://doi.org/10.1056/NEJMoa012914 CrossRefPubMed

Fukumura K, Kawazu M, Kojima S et al (2016) Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol 131:865–875. https://doi.org/10.1007/s00401-016-1536-2 CrossRefPubMed

Diamond C, Taylor TH, Aboumrad T, Anton Culver H (2006) Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer 106:128–135. https://doi.org/10.1002/cncr.21562 CrossRefPubMed

Besson C, Goubar A, Gabarre J et al (2001) Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 98:2339–2344CrossRefPubMed

Shiels MS, Pfeiffer RM, Besson C et al (2016) Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol 174:417–424. https://doi.org/10.1111/bjh.14073 CrossRefPubMedPubMedCentral

Gavrilovic IT, Hormigo A, Yahalom J et al (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570–4574. https://doi.org/10.1200/JCO.2006.06.6910 CrossRefPubMed

Nayak L, Hedvat C, Rosenblum MK et al (2011) Late relapse in primary central nervous system lymphoma: clonal persistence. Neuro-oncology 13:525–529. https://doi.org/10.1093/neuonc/nor014 CrossRefPubMedPubMedCentral

Zheng M, Perry AM, Bierman P et al (2017) Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma. Neuropathology 37:509–516. https://doi.org/10.1111/neup.12405 CrossRefPubMed

10.

Yamada S, Ishida Y, Matsuno A, Yamazaki K (2015) Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leuk Lymphoma 56:2141–2145. https://doi.org/10.3109/10428194.2014.979413 CrossRefPubMed

11.

Nakamura T, Tateishi K, Niwa T et al (2016) Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol 42:279–290. https://doi.org/10.1111/nan.12259 CrossRefPubMed

12.

Ngo VN, Young RM, Schmitz R et al (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470:115–119. https://doi.org/10.1038/nature09671 CrossRefPubMed

13.

Lim K-H, Yang Y, Staudt LM (2012) Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev 246:359–378. https://doi.org/10.1111/j.1600-065X.2012.01105.x CrossRefPubMedPubMedCentral

14.

Fitzgerald KA, Palsson-McDermott EM, Bowie AG et al (2001) Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413:78–83. https://doi.org/10.1038/35092578 CrossRefPubMed

15.

Montesinos-Rongen M, Godlewska E, Brunn A et al (2011) Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol 122:791–792. https://doi.org/10.1007/s00401-011-0891-2 CrossRefPubMed

16.

Braggio E, Van Wier S, Ojha J et al (2015) Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res 21:3986–3994. https://doi.org/10.1158/1078-0432.CCR-14-2116 CrossRefPubMedPubMedCentral

17.

Vater I, Montesinos-Rongen M, Schlesner M et al (2015) The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia 29:677–685. https://doi.org/10.1038/leu.2014.264 CrossRefPubMed

18.

Gonzalez-Aguilar A, Idbaih A, Boisselier B et al (2012) Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 18:5203–5211. https://doi.org/10.1158/1078-0432.CCR-12-0845 CrossRefPubMed

19.

Ostrom QT, Gittleman H, Liao P et al (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro-oncology 19:v1–v88. https://doi.org/10.1093/neuonc/nox158 CrossRefPubMedPubMedCentral

20.

Lu S, Gao Q, Yu J et al (2016) Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor. Eur J Radiol 85:1722–1727. https://doi.org/10.1016/j.ejrad.2016.07.005 CrossRefPubMed

21.

Wang K, Sanchez-Martin M, Wang X et al (2017) Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. Leukemia 31:151–158. https://doi.org/10.1038/leu.2016.166 CrossRefPubMed

22.

Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909–1920. https://doi.org/10.1016/S0140-6736(16)00561-4 CrossRefPubMedPubMedCentral

23.

Goodman AM, Kato S, Bazhenova L et al (2017) Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 16:2598–2608. https://doi.org/10.1158/1535-7163.MCT-17-0386 CrossRefPubMedPubMedCentral

24.

Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545–15550. https://doi.org/10.1073/pnas.0506580102 CrossRefPubMedPubMedCentral

25.

Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282. https://doi.org/10.1182/blood-2003-05-1545 CrossRefPubMed

26.

Lee J-H, Jeong H, Choi J-W et al (2017) Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis. Sci Rep 7:659. https://doi.org/10.1038/s41598-017-01998-5 CrossRef

27.

Kraan W, Horlings HM, van Keimpema M et al (2013) High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J 3:e139–e139. https://doi.org/10.1038/bcj.2013.28 CrossRefPubMedPubMedCentral

28.

Treon SP, Cao Y, Xu L et al (2014) Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 123:2791–2796. https://doi.org/10.1182/blood-2014-01-550905 CrossRefPubMed

29.

Poulain S, Boyle EM, Tricot S et al (2015) Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma. Br J Haematol 170:285–287. https://doi.org/10.1111/bjh.13293 CrossRefPubMed

30.

Severson E, Vergilio J-A, Gay L et al (2017) PATH-20. Comprehensive genomic profiling comparing primary CNS lymphoma to systemic diffuse large B cell lymphoma reveals biomarkers indicating potential benefit from immune checkpoint inhibitors. Neuro-oncology 19:vi175–vi175. https://doi.org/10.1093/neuonc/nox168.711 CrossRefPubMedCentral

31.

Domanska UM, Kruizinga RC, Nagengast WB et al (2013) A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 49:219–230. https://doi.org/10.1016/j.ejca.2012.05.005 CrossRefPubMed

32.

Cao Y, Hunter ZR, Liu X et al (2015) The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia. Leukemia 29:169–176. https://doi.org/10.1038/leu.2014.187 CrossRefPubMed

33.

Cao Y, Hunter ZR, Liu X et al (2015) CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells. Br J Haematol 168:701–707. https://doi.org/10.1111/bjh.13200 CrossRefPubMed

34.

Pusic I, DiPersio JF (2010) Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr Opin Hematol 17:319–326. https://doi.org/10.1097/MOH.0b013e328338b7d5 CrossRefPubMed

35.

McDermott DH, Lopez J, Deng F et al (2011) AMD3100 is a potent antagonist at CXCR4(R334X), a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome. J Cell Mol Med 15:2071–2081. https://doi.org/10.1111/j.1582-4934.2010.01210.x CrossRefPubMedPubMedCentral

36.

Martínez-Trillos A, Pinyol M, Navarro A et al (2014) Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood 123:3790–3796. https://doi.org/10.1182/blood-2013-12-543306 CrossRefPubMed

37.

Hattori K, Sakata-Yanagimoto M, Suehara Y et al (2018) Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma. Cancer Sci 109:225–230. https://doi.org/10.1111/cas.13450 CrossRefPubMed

38.

Treon SP, Xu L, Hunter Z (2015) MYD88 mutations and response to ibrutinib in Waldenström’s macroglobulinemia. N Engl J Med 373:584–586. https://doi.org/10.1056/NEJMc1506192 CrossRefPubMed

39.

Wilson WH, Young RM, Schmitz R et al (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21:922–926. https://doi.org/10.1038/nm.3884 CrossRefPubMedPubMedCentral

40.

Hiemcke-Jiwa LS, Minnema MC, Radersma-van Loon JH et al (2017) The use of droplet digital PCR in liquid biopsies: a highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid. Hematol Oncol 21:E7. https://doi.org/10.1002/hon.2489 CrossRef

41.

Bruno A, Boisselier B, Labreche K et al (2014) Mutational analysis of primary central nervous system lymphoma. Oncotarget 5:5065–5075. https://doi.org/10.18632/oncotarget.2080 CrossRefPubMedPubMedCentral

42.

Chapuy B, Roemer MGM, Stewart C et al (2016) Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127:869–881. https://doi.org/10.1182/blood-2015-10-673236 CrossRefPubMedPubMedCentral

43.

Choi J-W, Kim Y, Lee J-H, Kim Y-S (2013) MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Hum Pathol 44:1375–1381. https://doi.org/10.1016/j.humpath.2012.10.026 CrossRefPubMed

44.

Takano S, Hattori K, Ishikawa E et al (2018) MyD88 mutation in elderly predicts poor prognosis in primary central nervous system lymphoma: multi-institutional analysis. World Neurosurg 112:e69–e73. https://doi.org/10.1016/j.wneu.2017.12.028 CrossRefPubMed

45.

Baur AS, Shaw P, Burri N et al (1999) Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood 94:1773–1781PubMed

46.

Guney S, Jardin F, Bertrand P et al (2012) Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes. Genes Chromosomes Cancer 51:858–867. https://doi.org/10.1002/gcc.21970 CrossRefPubMed

47.

Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993–1000CrossRefPubMed

48.

Sharpless NE (2005) INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 576:22–38. https://doi.org/10.1016/j.mrfmmm.2004.08.021 CrossRefPubMed

49.

Roussel MF (1999) The INK4 family of cell cycle inhibitors in cancer. Oncogene 18:5311–5317. https://doi.org/10.1038/sj.onc.1202998 CrossRefPubMed

50.

Dickson MA (2014) Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 20:3379–3383. https://doi.org/10.1158/1078-0432.CCR-13-1551 CrossRefPubMed

51.

DeMichele A, Clark AS, Tan KS et al (2015) CDK 4/6 inhibitor palbociclib (PD0332991) in Rb + advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res 21:995–1001. https://doi.org/10.1158/1078-0432.CCR-14-2258 CrossRefPubMed

52.

Finn RS, Crown JP, Lang I et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16:25–35. https://doi.org/10.1016/S1470-2045(14)71159-3 CrossRefPubMed

53.

Infante JR, Cassier PA, Gerecitano JF et al (2016) A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res 22:5696–5705. https://doi.org/10.1158/1078-0432.CCR-16-1248 CrossRefPubMedPubMedCentral

54.

Johnson DB, Dahlman KH, Knol J et al (2014) Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist 19:616–622. https://doi.org/10.1634/theoncologist.2014-0011 CrossRefPubMedPubMedCentral

55.

SHERR CJ, BESTEN den BERTWISTLED W, et al (2005) p53-dependent and -independent functions of the arf tumor suppressor. Cold Spring Harb Symp Quant Biol 70:129–137. https://doi.org/10.1101/sqb.2005.70.004 CrossRefPubMed

56.

Ozenne P, Eymin B, Brambilla E, Gazzeri S (2010) The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer 127:2239–2247. https://doi.org/10.1002/ijc.25511 CrossRefPubMed

57.

Xu-Monette ZY, Wu L, Visco C et al (2012) Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL rituximab-CHOP Consortium Program Study. Blood 120:3986–3996. https://doi.org/10.1182/blood-2012-05-433334 CrossRefPubMedPubMedCentral

58.

Birkbak NJ, Kochupurakkal B, Izarzugaza JMG et al (2013) Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS ONE 8:e80023. https://doi.org/10.1371/journal.pone.0080023 CrossRefPubMedPubMedCentral

59.

Peters S, Creelan B, Hellmann MD et al (2017) Abstract CT082: impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: an exploratory analysis of CheckMate 026. Cancer Res 77:CT082–CT082. https://doi.org/10.1158/1538-7445.AM2017-CT082 CrossRef

60.

Roberts SA, Gordenin DA (2014) Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer 14:786–800. https://doi.org/10.1038/nrc3816 CrossRefPubMedPubMedCentral

61.

Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128. https://doi.org/10.1126/science.aaa1348 CrossRefPubMedPubMedCentral

62.

Pfeifer GP, Denissenko MF, Olivier M et al (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21:7435–7451. https://doi.org/10.1038/sj.onc.1205803 CrossRefPubMed

63.

Pfeifer GP, You Y-H, Besaratinia A (2005) Mutations induced by ultraviolet light. Mutat Res 571:19–31. https://doi.org/10.1016/j.mrfmmm.2004.06.057 CrossRefPubMed

64.

Chalmers ZR, Connelly CF, Fabrizio D et al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9:34. https://doi.org/10.1186/s13073-017-0424-2 CrossRefPubMedPubMedCentral

65.

Karim LA, Wang P, de Guzman J et al (2017) Abstract 3724: PDL1 protein expression and tumor mutation burden in hematologic malignancies: correlation with Hodgkin and high grade lymphoma. Cancer Res 77:3724–3724. https://doi.org/10.1158/1538-7445.AM2017-3724 CrossRef

66.

Montesinos-Rongen M, Siebert R, Deckert M (2009) Primary lymphoma of the central nervous system: just DLBCL or not? Blood 113:7–10. https://doi.org/10.1182/blood-2008-04-149005 CrossRefPubMed

67.

Cady FM, O’Neill BP, Law ME et al (2008) Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol 26:4814–4819. https://doi.org/10.1200/JCO.2008.16.1455 CrossRefPubMedPubMedCentral

68.

Montesinos-Rongen M, Akasaka T, Zühlke-Jenisch R et al (2003) Molecular characterization of BCL6 breakpoints in primary diffuse large B-cell lymphomas of the central nervous system identifies GAPD as novel translocation partner. Brain Pathol 13:534–538CrossRefPubMed

69.

Montesinos-Rongen M, Zühlke-Jenisch R, Gesk S et al (2002) Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system. J Neuropathol Exp Neurol 61:926–933CrossRefPubMed

70.

Kramer MH, Hermans J, Wijburg E et al (1998) Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92:3152–3162PubMed

71.

Akyurek N, Uner A, Benekli M, Barista I (2012) Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 118:4173–4183. https://doi.org/10.1002/cncr.27396 CrossRefPubMed

72.

Horn H, Ziepert M, Becher C et al (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121:2253–2263. https://doi.org/10.1182/blood-2012-06-435842 CrossRefPubMed

73.

Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene Ciloleucel (AXI-CEL; KTE-C19) in patients with refractory aggressive non-hodgkin lymphomas (NHL): primary results of the pivotal trial ZUMA-1. Hematol Oncol 35:28–28. https://doi.org/10.1002/hon.2437_7 CrossRef

74.

Locke FL, Neelapu SS, Bartlett NL et al (2017) Abstract CT019: primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). Cancer Res 77:CT019–CT019. https://doi.org/10.1158/1538-7445.AM2017-CT019 CrossRef

Title: Characterization of genomic alterations in primary central nervous system lymphomas
Authors: Soheil Zorofchian
Hanadi El-Achi
Yuanqing Yan
Yoshua Esquenazi
Leomar Y. Ballester
Publication date: 01-12-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2990-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Characterization of genomic alterations in primary central nervous system lymphomas

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma

Gamma knife radiosurgery for recurrent gliomas

Prognosis and treatment outcomes of central neurocytomas: clinical interrogation based on a single center experience

Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma

Pre-irradiation intensive induction and marrow-ablative consolidation chemotherapy in young children with newly diagnosed high-grade brainstem gliomas: report of the “head-start” I and II clinical trials

The prediction of the tumor size of a vestibular schwannoma by clinical performance and vestibular function tests